Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib

被引：9

作者：

Heigener, David F. ^{[1
]}

Reck, Martin ^{[1
]}

机构：

[1] Hosp Grosshansdorf, D-22927 Hamburg, Germany

来源：

ADVANCES IN THERAPY | 2011年 / 28卷 / 02期

关键词：

EGFR; erlotinib; gefitinib; mutation; non-small cell lung cancer; TYROSINE KINASE; EGFR MUTATION; PHASE-II; RESISTANCE; MET; CARBOPLATIN; PACLITAXEL; INHIBITOR;

D O I：

10.1007/s12325-010-0096-4

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Epidermal growth factor receptor (EGFR)-activating mutations in non-small cell lung cancer (NSCLC) are molecular targets for treatment with gefitinib and erlotinib, often resulting in improved response and prolonged progression-free survival. Resistance to these drugs, which develops during treatment, is a problem of paramount importance. Several mechanisms of "acquired resistance" have been discovered and treatments for this specific entity are on the horizon.

引用

页码：126 / 133

页数：8

共 35 条

[1]

[Anonymous], J CLIN ONCOL S

[2]

[Anonymous], J CLIN ONCOL S

[3] Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT) [J].

Boyer, M. J. ;

Blackhall, F. H. ;

Park, K. ;

Barrios, C. H. ;

Krzakowski, M. J. ;

Taylor, I. ;

Liang, J. Q. ;

Denis, L. J. ;

O'Connell, J. P. ;

Ramalingam, S. S. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)

[4] Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non-Small-Cell Lung Cancer Patients [J].

Cappuzzo, Federico ;

Marchetti, Antonio ;

Skokan, Margaret ;

Rossi, Elisa ;

Gajapathy, Sujatha ;

Felicioni, Lara ;

del Grammastro, Maela ;

Sciarrotta, Maria Grazia ;

Buttitta, Fiamma ;

Incarbone, Matteo ;

Toschi, Luca ;

Finocchiaro, Giovanna ;

Destro, Annarita ;

Terracciano, Luigi ;

Roncalli, Massimo ;

Alloisio, Marco ;

Santoro, Armando ;

Varella-Garcia, Marileila .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) :1667-1674

[5]

Ciardiello Fortunato, 2005, Future Oncol, V1, P221, DOI 10.1517/14796694.1.2.221

[6] MET as a target for treatment of chest tumors [J].

Cipriani, Nicole A. ;

Abidoye, Oyewale O. ;

Vokes, Everett ;

Salgia, Ravi .

LUNG CANCER, 2009, 63 (02) :169-179

[7] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].

Engelman, Jeffrey A. ;

Zejnullahu, Kreshnik ;

Mitsudomi, Tetsuya ;

Song, Youngchul ;

Hyland, Courtney ;

Park, Joon Oh ;

Lindeman, Neal ;

Gale, Christopher-Michael ;

Zhao, Xiaojun ;

Christensen, James ;

Kosaka, Takayuki ;

Holmes, Alison J. ;

Rogers, Andrew M. ;

Cappuzzo, Federico ;

Mok, Tony ;

Lee, Charles ;

Johnson, Bruce E. ;

Cantley, Lewis C. ;

Janne, Pasi A. .

SCIENCE, 2007, 316 (5827) :1039-1043

[8]

HEIGENER D, 2010, ANN ONCOL S8, V21

[9] Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer [J].

Jackman, David ;

Pao, William ;

Riely, Gregory J. ;

Engelman, Jeffrey A. ;

Kris, Mark G. ;

Jaenne, Pasi A. ;

Lynch, Thomas ;

Johnson, Bruce E. ;

Miller, Vincent A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (02) :357-360

[10] RETRACTED: Phase II Study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small-Cell Lung Cancer (Retracted article. See vol. 30, pg. 4179, 2012) [J].

Karp, Daniel D. ;

Paz-Ares, Luis G. ;

Novello, Silvia ;

Haluska, Paul ;

Garland, Linda ;

Cardenal, Felipe ;

Blakely, L. Johnetta ;

Eisenberg, Peter D. ;

Langer, Corey J. ;

Blumenschein, George, Jr. ;

Johnson, Faye M. ;

Green, Stephanie ;

Gualberto, Antonio .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) :2516-2522

← 1 2 3 4 →